Merck’s MRK strong foothold in the oncology space is propelled by its biggest revenue driver, Keytruda. The blockbuster PD-L1 inhibitor alone accounted for more than 50% of the company’s ...

Roche has found redemption in a precision medicine approach following an earlier Tecentriq trial flop in a broader bladder ...